Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Federation Francophone de Cancerologie Digestive: Clinical Trials & FDA Approval Profile

Federation Francophone de Cancerologie Digestive (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (3 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)118 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Federation Francophone de Cancerologie Digestive
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)7 (3)
Completed vs Stopped Early5 / 0 (0.0%)
Median Closed Actual Enrollment118 participants
Physical Hospital Site Disclosure99.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Federation Francophone de Cancerologie Digestive
Hospital Research SiteLocationShared Protocols
Institut Sainte CatherineAvignon3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Federation Francophone de Cancerologie Digestive
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07270991Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric AdenocarcinomaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Federation Francophone de Cancerologie Digestive Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI